Pembrolizumab alone beats chemo in dMMR endometrial cancer trial

The phase 3 KEYNOTE-C93/GOG-3064/ENGOT-en15 trial compared first-line pembrolizumab monotherapy with carboplatin plus paclitaxel in 299 participants with mismatch repair-deficient advanced or recurrent endometrial cancer. The trial reported median progression-free survival of 38.2 months with pembrolizumab versus 8.4 months with chemotherapy (HR 0.57, p=0.0002), while overall survival did not meet the prespecified significance criterion at this interim analysis; grade 3 or higher treatment-related adverse events occurred less often with pembrolizumab (18% vs 51%). The authors note the study did not compare pembrolizumab monotherapy against the current standard of immunotherapy plus chemotherapy.

Most relevant for: Patients with inoperable, stage III or IV, persistent, advanced, or recurrent mismatch repair-deficient endometrial cancer being considered for first-line systemic therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.